Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)
China · Delayed Price · Currency is CNY 43.40
+0.28 (0.65%)
Sep 23, 2026, 3:00 PM CST
Hangzhou Biotest Biotech Market Cap
Hangzhou Biotest Biotech has a market cap or net worth of 6.35 billion as of September 23, 2026. Its market cap has increased by 3.43% in one year.
Market Cap
6.35B
Enterprise Value
5.19B
Revenue
459.42M
Ranking
n/a
PE Ratio
281.19
Stock Price
43.40
ChartMarket Cap Chart
Since September 8, 2021, Hangzhou Biotest Biotech's market cap has decreased from 8.23B to 6.35B, a decrease of -22.81%. That is a compound annual growth rate of -5.00%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 23, 2026 | 6.35B | 14.88% |
| Dec 31, 2025 | 5.53B | 60.13% |
| Dec 31, 2024 | 3.45B | 6.92% |
| Dec 29, 2023 | 3.23B | -34.48% |
| Dec 30, 2022 | 4.93B | -33.91% |
| Dec 31, 2021 | 7.46B | -9.37% |
| Sep 8, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Novogene | 7.36B |
| Chengdu Kanghua Biological Products | 7.06B |
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 7.03B |
| Jiangsu Aidea Pharmaceutical Group | 6.98B |
| PharmaResources (Shanghai) | 6.96B |
| Zhejiang Ausun Pharmaceutical | 6.53B |
| R&G PharmaStudies | 6.25B |
| Youcare Pharmaceutical Group | 5.96B |